Canaccord Genuity Reiterates Buy Rating on Biodesix, Inc.
Canaccord Genuity maintains its buy rating for Biodesix, Inc. with a $27 price target.
Key Points
- Canaccord Genuity reiterated its buy rating on Biodesix, Inc. with a price target of $27 as of June 18, 2026.
- Biodesix, Inc. shares are trading at $15.22 with a market cap of approximately $157.6 million on the NasdaqGM.
- Insider transactions include recent sales by executives, while analysts maintain a strong buy consensus with a mean target price of $29.6.
On June 18, 2026, Canaccord Genuity reiterated its buy rating for Biodesix, Inc. (NasdaqGM: BDSX), setting a price target of $27. This reflects continued confidence in the company's prospects.
Other Institutional Activity in Biodesix, Inc.
Several institutional investors have been active in Biodesix, Inc. AIGH Capital Management LLC added 758,328 shares, bringing its total to 758,328 shares valued at approximately $11 million. Telemark Asset Management, LLC increased its stake by 162,000 shares to 489,824 shares, worth about $7.1 million. Aberdeen Group PLC boosted its holdings by 196,013 shares, ending with 458,438 shares valued at around $6.6 million.
Biodesix, Inc. Stock Up 10.4%
Shares of Biodesix, Inc. are trading at $15.22 on the NasdaqGM. The company has a market cap of about $157.6 million and a forward P/E ratio that is not meaningful due to its lack of profitability. The stock's beta is 0.593, indicating lower volatility compared to the market. Over the past year, the stock has traded between $5.00 and $20.21, with a 50-day moving average of $13.95 and a 200-day moving average of $10.76.
Recent Earnings
Biodesix, Inc. reported revenue of $96.1 million with a growth rate of 42.3%. However, the company has a negative net margin of -33.3% and a return on equity of -316.5%. The next earnings release is expected on August 6, 2026.
Insider Buying and Selling at Biodesix, Inc.
Recent insider activity at Biodesix, Inc. includes several sales. On February 23, 2026, CFO Robin Harper Cowie sold 535 shares at an average price of $12.78. Chief Accounting Officer Chris Vazquez and Chief Commercial Officer Kieran O'Kane also sold shares at the same price on the same date.
Analysts Set New Price Targets
On June 18, 2026, Canaccord Genuity maintained its buy rating with a $27 price target. Just a few days earlier, on June 15, 2026, HC Wainwright & Co. initiated coverage with a buy rating and a $26 target. The general consensus among analysts is a strong buy, with an average target price of $29.6 based on five analyst opinions.
About Biodesix, Inc.
Biodesix, Inc. is a healthcare company based in Louisville, Colorado, specializing in diagnostic solutions. It provides blood-based lung tests and other diagnostic services to assess lung cancer risk and guide treatment decisions. The company also offers a range of support services for biopharmaceutical and diagnostic companies. Led by CEO Scott Hutton, Biodesix operates with approximately 334 employees.
Bottom Line
Biodesix, Inc. continues to attract attention from analysts and institutional investors, as evidenced by Canaccord Genuity's reiterated buy rating and several institutional moves. The company is focused on innovative diagnostics, though it faces financial challenges with negative margins and earnings. Investors should note that the information reflects past data and may not indicate current performance.
Get Biodesix, Inc. alerts
New 13F filings, insider trades, and analyst moves on $BDSX, sent to your inbox. Free, and you can unsubscribe anytime.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.